Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754805 | 0.85 | HTR2C (0.54) | PARP1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1170552 | 0.85 | HTR2C (0.54) | PARP1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31329634 | 0.85 | HTR2C (0.54) | PARP1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21751143 | 0.81 | PARP1 (0.47) | CYP3A4CYP2C9CYP2C19PARP1PSEN1 | |
| SCHEMBL21326064 | 0.81 | PARP1 (0.47) | CYP3A4CYP2C9CYP2C19PARP1PSEN1 | |
| SCHEMBL8272821 | 0.81 | PREP (0.65) | PREPACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13532966 | 0.81 | PREP (0.65) | PREPACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2391599 | 0.81 | AOC3 (0.52) | PREPCYP2C19ACE2PARP1PSEN1 | |
| SCHEMBL4621183 | 0.81 | PARP1 (0.48) | CYP3A4CYP2C9CYP2C19PARP1PSEN1 | |
| SCHEMBL11179612 | 0.81 | NPC1 (0.51) | PREPCYP3A4CYP2C9CYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| CN-101370776-A | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARM INC (US) | 2009-02-18 | — | — | CN | disclosed |
| EP-1957458-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | Elan Pharmaceuticals Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007064914-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | PREP 411/4885CYP3A4 982/4885CYP2C9 763/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | PREP 411/4885CYP3A4 982/4885CYP2C9 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.